UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 24, 1995
CYTRX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-15327 58-1642740
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
154 Technology Parkway, Norcross, Georgia 30092
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (770) 368-9500
(Former name or former address, if changed since last report)
Item 5 - Other Events
On October 24, 1995, CytRx Corporation announced that Glaxo Wellcome PLC had
informed the company of its decision to cease development of RheothRx and its
intention to terminate its license. Since May 1994, RheothRx has been under
evaluation in the multi-national CORE study (Collaborative Organization for
RheothRx Evaluation) for the treatment of heart attack. Results of the trial
indicated that RheothRx showed benefit only in certain clinical evaluations
and were limited to high dose levels associated with unacceptable toxicity.
Lower dosages of the drug were not associated with any clinical benefit.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CYTRX CORPORATION
(Registrant)
Date: November 7, 1995 By: /s/ Mark W. Reynolds
Mark W. Reynolds
Controller, Chief Accounting Officer
